Mingxiao Li1, Dake Yang2, Guy Brock2, Ralph J Knipp3, Michael Bousamra4, Michael H Nantz3, Xiao-An Fu5. 1. Department of Chemical Engineering, University of Louisville, Louisville, KY 40292, United States. 2. Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY 40292, United States. 3. Department of Chemistry, University of Louisville,Louisville, KY 40292, United States. 4. Department of Cardiothoracic Surgery, University of Louisville, Louisville, KY 40292, United States; James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40292, United States. 5. Department of Chemical Engineering, University of Louisville, Louisville, KY 40292, United States. Electronic address: xiaoan.fu@louisville.edu.
Abstract
OBJECTIVE: Lung cancer dysregulations impart oxidative stress which results in important metabolic products in the form of volatile organic compounds (VOCs) in exhaled breath. The objective of this work is to use statistical classification models to determine specific carbonyl VOCs in exhaled breath as biomarkers for detection of lung cancer. MATERIALS AND METHODS: Exhaled breath samples from 85 patients with untreated lung cancer, 34 patients with benign pulmonary nodules and 85 healthy controls were collected. Carbonyl compounds in exhaled breath were captured by silicon microreactors and analyzed by Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS). The concentrations of carbonyl compounds were analyzed using a variety of statistical classification models to determine which compounds best differentiated between the patient sub-populations. Predictive accuracy of each of the models was assessed on a separate test data set. RESULTS: Six carbonyl compounds (C(4)H(8)O, C(5)H(10)O, C(2)H(4)O(2), C(4)H(8)O(2), C(6)H(10)O(2), C(9)H(16)O(2)) had significantly elevated concentrations in lung cancer patients vs. CONTROLS: A model based on counting the number of elevated compounds out of these six achieved an overall classification accuracy on the test data of 97% (95% CI 92%-100%), 95% (95% CI 88%-100%), and 89% (95% CI 79%-99%) for classifying lung cancer patients vs. non-smokers, current smokers, and patients with benign nodules, respectively. These results were comparable to benchmarking based on established statistical and machine-learning methods. The sensitivity in each case was 96% or higher, with specificity ranging from 64% for benign nodule patients to 86% for smokers and 100% for non-smokers. CONCLUSION: A model based on elevated levels of the six carbonyl VOCs effectively discriminates lung cancer patients from healthy controls as well as patients with benign pulmonary nodules.
OBJECTIVE:Lung cancer dysregulations impart oxidative stress which results in important metabolic products in the form of volatile organic compounds (VOCs) in exhaled breath. The objective of this work is to use statistical classification models to determine specific carbonyl VOCs in exhaled breath as biomarkers for detection of lung cancer. MATERIALS AND METHODS: Exhaled breath samples from 85 patients with untreated lung cancer, 34 patients with benign pulmonary nodules and 85 healthy controls were collected. Carbonyl compounds in exhaled breath were captured by silicon microreactors and analyzed by Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS). The concentrations of carbonyl compounds were analyzed using a variety of statistical classification models to determine which compounds best differentiated between the patient sub-populations. Predictive accuracy of each of the models was assessed on a separate test data set. RESULTS: Six carbonyl compounds (C(4)H(8)O, C(5)H(10)O, C(2)H(4)O(2), C(4)H(8)O(2), C(6)H(10)O(2), C(9)H(16)O(2)) had significantly elevated concentrations in lung cancerpatients vs. CONTROLS: A model based on counting the number of elevated compounds out of these six achieved an overall classification accuracy on the test data of 97% (95% CI 92%-100%), 95% (95% CI 88%-100%), and 89% (95% CI 79%-99%) for classifying lung cancerpatients vs. non-smokers, current smokers, and patients with benign nodules, respectively. These results were comparable to benchmarking based on established statistical and machine-learning methods. The sensitivity in each case was 96% or higher, with specificity ranging from 64% for benign nodule patients to 86% for smokers and 100% for non-smokers. CONCLUSION: A model based on elevated levels of the six carbonyl VOCs effectively discriminates lung cancerpatients from healthy controls as well as patients with benign pulmonary nodules.
Authors: Chunxia Su; Mathias Meyer; Robert Pirker; Wieland Voigt; Jingyun Shi; Lothar Pilz; Rudolf M Huber; Yilong Wu; Jinghong Wang; Yonglan He; Xuan Wang; Jian Zhang; Xiuyi Zhi; Meiqi Shi; Bo Zhu; Stefan S Schoenberg; Thomas Henzler; Christian Manegold; Caicun Zhou; Eric Dominic Roessner Journal: Transl Lung Cancer Res Date: 2016-08
Authors: Mumiye A Ogunwale; Ralph J Knipp; Clint N Evrard; Lee M Thompson; Michael H Nantz; Xiao-An Fu Journal: Chemphyschem Date: 2019-03-05 Impact factor: 3.102
Authors: Eline Janssens; Zoë Mol; Lore Vandermeersch; Sabrina Lagniau; Karim Y Vermaelen; Jan P van Meerbeeck; Christophe Walgraeve; Elly Marcq; Kevin Lamote Journal: Front Oncol Date: 2022-05-06 Impact factor: 5.738
Authors: Ahmed Shaffie; Ahmed Soliman; Xiao-An Fu; Michael Nantz; Guruprasad Giridharan; Victor van Berkel; Hadil Abu Khalifeh; Mohammed Ghazal; Adel Elmaghraby; Ayman El-Baz Journal: Sci Rep Date: 2021-02-25 Impact factor: 4.379